Close Menu

Bruker

The company said that it plans to use funds from its recent $18 million Series B round to drive instrument sales and develop AI tools for data analysis.

Canopy offers products and services for gene editing, gene expression analysis and regulation, and bioprocessing, as well as a multi-omic immune profiling platform.

The pair are working on reagents and mass spec approaches to improve isolation and analysis of crosslinked peptides for protein interaction and structural studies.

The collaborators will develop methods using Bruker's timsTOF Pro for structural and protein interaction work that the company plans to commercialize.

The company reported Q2 revenues of $424.6 million, down from $490.2 million in Q2 2019 but beating the consensus Wall Street estimate of $390.9 million.

The FluoroType SARS-CoV-2 plus real-time PCR test can distinguish SARS-CoV-2 from other coronaviruses that can cause the common cold.

The company said that the better-than-expected projections were driven mainly by stronger demand for its life science products.

Bruker's system has seen strong uptake among proteomics researchers, but its ability to generate large amounts of complex data has led to analysis challenges.

While there were a few new mass spectrometry instrument introductions, vendors focused primarily on software and sample separation advances.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.